Resources
At Albrem Biopharma, we specialize in analyzing and selecting highly active, modified proteins derived from naturally occurring sequences, leveraging targeted modifications produced via cell-free synthesis. The Albrem team possesses extensive expertise in advanced protein production and characterization platforms, with demonstrated success in supporting programs from early development through scale-up and technology transfer.
Our capabilities include small-scale and bioreactor-based protein expression and purification, encompassing optimization of upstream and downstream processes to enable seamless scale-up and robust tech transfer. In addition, we have significant experience in cell-free protein synthesis (CFPS), enabling rapid DNA-to-protein translation at both microgram and milligram scales, with established methods for process intensification, scale-up, and transferability across multiple protein products.
We apply well-validated strategies in protein formulation and stability assessment, ensuring molecular integrity, functionality, and long-term product performance. Complementing these efforts, our team is proficient in analytical method development, protein testing and characterization, utilizing advanced techniques including HPLC, CE, MS, and SPR to generate high-resolution, reproducible data that underpin both product development and regulatory submissions.
Relevant Article Citations
Rezvani RN, Aw R, Chan W, Satish K, Chen H, Lavy A, Rimal S, Patel DA, Rao G, Swartz JR, DeLisa MP, Kvam E, Karim AS, Kruger A, Kightlinger W, Jewett MC. Scalable Cell-Free Production of Active T7 RNA Polymerase. Biotechnol. Bioengn. 2025 (January); 1-10. doi: 10.1002/bit.28993.
House RV, Broge TA, Suscovich TJ, Snow DM, Tomic MT, Nonet G, Bajwa K, Zhu G, Martinez Z, Hackett K, Earnhart CG, Dorsey NM, Hopkins SA, Natour DS, Davis HD, Anderson MS, Gainey MR, Cobb RR. Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics. PLoS One. 2022 Jun 3;17(6):e0267796. doi: 10.1371/journal.pone.0267796. eCollection 202
Hastie KM, Li H, Bedinger D, Schendel SL, Dennison SM, Li K, Rayaprolu V, Yu X, Mann C, Zandonatti M, Diaz Avalos R, Zyla D, Buck T, Hui S, Shaffer K, Hariharan C, Yin J, Olmedillas E, Enriquez A, Parekh D, Abraha M, Feeney E, Horn GQ; CoVIC-DB team1, Aldon Y, Ali H, Aracic S, Cobb RR, Federman RS, Fernandez JM, Glanville J, Green R, Grigoryan G, Lujan Hernandez AG, Ho DD, Huang KA, Ingraham J, Jiang W, Kellam P, Kim C, Kim M, Kim HM, Kong C, Krebs SJ, Lan F, Lang G, Lee S, Leung CL, Liu J, Lu Y, MacCamy A, McGuire AT, Palser AL, Rabbitts TH, Rikhtegaran Tehrani Z, Sajadi MM, Sanders RW, Sato AK, Schweizer L, Seo J, Shen B, Snitselaar JL, Stamatatos L, Tan Y, Tomic MT, van Gils MJ, Youssef S, Yu J, Yuan TZ, Zhang Q, Peters B, Tomaras GD, Germann T, Saphire EO. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study. Science. 2021 Oct 22;374(6566):472-478. doi: 10.1126/science.abh2315. Epub 2021 Sep 23.
Snow DM, Cobb RR, Martinez J, Finger-Baker I, Collins L, Terpening S, Syar ES, Niemuth N, Kobs D, Barnewall R, Farr-Jones S, Marks JD, Tomic MT. A Monoclonal Antibody Combination against both Serotypes A and B Botulinum Toxin Prevents Inhalational Botulism in a Guinea Pig Model. Toxins (Basel). 2021 Jan 5;13(1):31. doi: 10.3390/toxins13010031
Tomic MT, Farr-Jones S, Syar ES, Niemuth N, Kobs D, Hackett MJ, Espinoza Y, Martinez Z, Pham K, Snow DM, Marks JD, Cobb RR. Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model. Toxins (Basel). 2021 Sep 21;13(9):671. doi: 10.3390/toxins13090671.
Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT. Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats. Toxins (Basel). 2019 Jun 17;11(6). pii: E345.
Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD. Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model. Toxins (Basel). 2019 Apr 6;11(4). pii: E208.
Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT. An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoS One. 2018 May 10;13(5):e0197011. doi:10.1371/journal.pone.0197011. eCollection 2018. PubMed PMID: 29746518; PubMed Central PMCID: PMC5944936.
Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH. Antibody engineering to improve manufacturability. Protein Expr Purif. 2018 Sep;149:75-83. doi:10.1016/j.pep.2018.04.003. Epub 2018 Apr 12. PubMed PMID: 29655788.
Nayak SU, Griffiss JM, McKenzie R, Fuchs EJ, Jurao RA, An AT, Ahene A, Tomic M, Hendrix CW, Zenilman JM. Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob Agents Chemother. 2014 Sep;58(9):5047-53. doi: 10.1128/AAC.02830-14. Epub 2014 Jun 9. PubMed PMID: 24913160; PubMed Central PMCID: PMC4135817.
Meng Q, Li M, Silberg MA, Conrad F, Bettencourt J, To R, Huang C, Ma J, Meyer K, Shimizu R, Cao L, Tomic MT, Marks JD. Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein. Anal Biochem. 2012 Feb 15;421(2):351-61. Epub 2011 Oct 6.
Teshima G, Li MX, Danishmand R, Obi C, To R, Huang C, Kung J, Lahidji V, Freeberg J, Thorner L, Tomic M. Separation of oxidized variants of a monoclonal antibody by anion-exchange. J Chromatogr A. 2011 Apr 15;1218(15):2091-7. Epub 2010 Nov 16.
Carol Huang, Qi Meng, Mingxiang Li, Jeffrey Bettencourt, Glen Teshima, Chidi Obi, Michael Silberg, James Marks MD, Robert To, Jacob Kung, Joel Freeberg and Milan Tomic (2009) Development, Preparation and Characterization of Subdomains of Type A Botulinum Neurotoxin.